Using response-guided target identification, 3T has discovered novel targets for the treatment of solid tumors. These targets are broadly expressed across tumor indications, while having minimal normal tissue expression.

Oncology Pipeline

Target Type Discovery Proof of Concept Lead Optimization Phase 1 Modality
Public CTA
TCR-T
Novel CTAs
(Multiple)
Non CTAs
(Multiple)

Oncology Pipeline

Target Type Phase Modality
Public CTA
Lead Optimization
TCR-T
Novel CTAs
(Multiple)
Proof of Concept
Non CTAs
(Multiple)
Proof of Concept

The therapeutic modalities pursued for targeting the novel targets include TCR-T cells (adoptive T-cell therapies), TCR mimic compounds and peptides, including mimotopes, for cancer vaccines.

The utility of the 3T platform is not limited to discovery of novel targets and therapies in oncology, but extends to all T cell mediated diseases, including autoimmune disease, allergies or infectious diseases.